Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin

Weerawat ManosuthiSomnuek SungkanuparphAmmarin ThakkinstianSasivimol RattanasiriAchara ChaovavanichWisit PrasithsirikulSirirat LikanonsakulKiat RuxrungthamThailand Ministry of Public HealthMahidol UniversityThe HIV Netherlands Australia Thailand Research CollaborationBamrasnaradura Infectious Disease Institute2018-08-202018-08-202006-07-15Clinical Infectious Diseases. Vol.43, No.2 (2006), 253-255105848382-s2.0-33745700384https://repository.li.mahidol.ac.th/handle/20.500.14594/23318Seventy human immunodeficiency virus (HIV)-infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P = .048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P > .05). © 2006 by the Infectious Diseases Society of America. All rights reserved.Mahidol UniversityImmunology and MicrobiologyPlasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicinArticleSCOPUS10.1086/505210